Sustained Efficacy and Low Rate of Adverse Events of Dupilumab in Type‐2 CRSwNP Over 48 Months
Year: 2025
Type: article
Study design: Observational Study
Source: The Laryngoscope
DOI: 10.1002/lary.32205
Institution: Azienda Ospedaliero-Universitaria Careggi
Language: English
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409699116